NCT02909777 2026-02-11
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
3 trialsNCT01742988 2021-05-06
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Curis, Inc.
Phase 1 Completed
NCT02307240 2019-09-03
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Curis, Inc.
Phase 1 Completed